Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics Limited has announced a strategic collaboration with BAMF Health to manufacture and administer its novel radiotracer 18F-RAD 101 for a Phase 2b imaging study targeting brain metastasis. BAMF Health will be the first clinical trial site, expected to begin patient enrollment in the fourth quarter of 2024, utilizing its advanced radiopharmacy capabilities. This partnership aims to accelerate the delivery of innovative cancer treatments, potentially benefiting patients globally.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
